312 related articles for article (PubMed ID: 30442716)
21. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
[TBL] [Abstract][Full Text] [Related]
22. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
Fournier D; Jouneau S; Bouzillé G; Polard E; Osmont MN; Scailteux LM
Pulm Pharmacol Ther; 2022 Oct; 76():102149. PubMed ID: 35918026
[TBL] [Abstract][Full Text] [Related]
23. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
24. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
25. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
[TBL] [Abstract][Full Text] [Related]
26. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration.
Ikeda S; Sekine A; Baba T; Kato T; Katano T; Tabata E; Shintani R; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
Medicine (Baltimore); 2022 Jun; 101(22):e29232. PubMed ID: 35665728
[TBL] [Abstract][Full Text] [Related]
29. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
Belhassen M; Dalon F; Nolin M; Van Ganse E
Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
[TBL] [Abstract][Full Text] [Related]
30. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis.
Perelas A; Glennie J; van Kerkhove K; Li M; Scheraga RG; Olman MA; Culver DA
Pulm Pharmacol Ther; 2019 Dec; 59():101839. PubMed ID: 31518649
[TBL] [Abstract][Full Text] [Related]
31. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
[TBL] [Abstract][Full Text] [Related]
32. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
Corral M; Chang E; Broder MS; Gokhale S; Reddy SR
J Comp Eff Res; 2020 Sep; 9(13):933-943. PubMed ID: 32851849
[No Abstract] [Full Text] [Related]
33. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
[TBL] [Abstract][Full Text] [Related]
34. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
[TBL] [Abstract][Full Text] [Related]
35. The safety of new drug treatments for idiopathic pulmonary fibrosis.
Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
[TBL] [Abstract][Full Text] [Related]
36. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
[TBL] [Abstract][Full Text] [Related]
37. Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia.
Cox IA; de Graaff B; Corte TJ; Glaspole I; Chambers DC; Moodley Y; Teoh A; Walters EH; Palmer AJ
Aust Health Rev; 2021 Dec; 45(6):718-727. PubMed ID: 34706811
[TBL] [Abstract][Full Text] [Related]
38. Nintedanib for Idiopathic Pulmonary Fibrosis.
Tepede A; Yogaratnam D
J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
[TBL] [Abstract][Full Text] [Related]
39. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
Sgalla G; Comes A; Richeldi L
Expert Opin Drug Saf; 2021 Sep; 20(9):1035-1048. PubMed ID: 33881959
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
